Usefulness of CHA 2 DS 2 -VASc score to predict mortality and hospitalization in patients with inflammatory arthritis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Wiley on behalf of the Asia Pacific League of Associations for Rheumatology Country of Publication: England NLM ID: 101474930 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1756-185X (Electronic) Linking ISSN: 17561841 NLM ISO Abbreviation: Int J Rheum Dis Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Oxford, UK] : Wiley on behalf of the Asia Pacific League of Associations for Rheumatology
    • Subject Terms:
    • Abstract:
      Background: Inflammatory arthritis including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are disorders at increased risk of morbidity and mortality for which a validated prognostic tool for facilitating clinical management is needed. CHA 2 DS 2 -VASc (congestive heart failure/hypertension/age diabetes/stroke/vascular disease/age/sex category) score was initially conceived and used to estimate thromboembolic risk in non-valvular atrial fibrillation, and then successfully applied in community populations with sinus rhythm. We tested CHA 2 DS 2 -VASc-score as a prognosticator of adverse outcomes in patients in sinus rhythm with RA/AS/PsA.
      Methods: Between March 2014 and March 2015, 414 patients (214 RA, 75 AS, 125 PsA) in sinus rhythm without cardiac disease were consecutively analyzed and prospectively followed-up. Primary and co-primary end-points were a composite of all-cause death/all-cause hospitalization and CV death/CV hospitalization, respectively.
      Results: Patients were divided into LOWscore and HIGHscore groups if CHA 2 DS 2 -VASc was = 0/1 point or greater than 1 point, respectively. The HIGHscore group comprised 190 patients who were older with higher prevalence of CV risk factors and arthritis disease activity than 224 LOWscore patients. During a follow up of 36 months, the event rate for primary and co-primary end-point was 37% and 12% in the HIGHscore vs 22% and 4% in LOWscore group (P = .001 and .002 respectively). At multivariate Cox regression analysis CHA 2 DS 2 -VASc-score was related to primary end-point (hazards ratio [HR] 1.30 [1.07-1.59], P = .009) and co-primary end-point (HR 1.35 [1.01-1.79], P = .04) independently of traditional CV risk factors analyzed individually and indexes of inflammation or disease duration.
      Conclusion: CHA 2 DS 2 -VASc-score accurately identifies in the mid-term patients in sinus rhythm with RA/AS/PsA at different risks for CV and non-CV mortality and hospitalization.
      (© 2019 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.)
    • References:
      Gonzales A, Maradit Kremers H, Crowson CS, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum. 2007;56:3583-3587.
      Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59:1690-1697.
      John H, Kitas G. Inflammatory arthritis as a novel risk factor for cardiovascular disease. Eur J Intern Med. 2012;23:575-579.
      Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun. 2007;28:69-75.
      Han C, Robinson Jr DW, Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2006;33:2167-2172.
      Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50:e1-e88.
      Lip GYH, Collet J-P, Haude M, Huber K. Management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing PCI: A Summary of the Joint Consensus Document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Eur Heart J. 2018;39:2847-2850.
      Mazzone C, Cioffi G, Carriere C, et al. Predictive role of CHA2DS2-VASc score for cardiovascular events and death in patients with arterial hypertension and stable sinus rhythm. Eur J Prev Cardiol. 2017;24:1584-1593.
      Hai JJ, Chan PH, Chan YH, et al. Prediction of thromboembolic events in heart failure patients in sinus rhythm: the hong kong heart failure registry. PLoS ONE. 2016;11:1-14.
      Parsons C, Patel SI, Cha S, et al. CHA2DS2-VASc score: a predictor of thromboembolic events and mortality in patients with an implantable monitoring device without atrial fibrillation. Mayo Clin Proc. 2017;92:360-369.
      Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GYH. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA. 2015;314:E1-E9.
      Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-2581.
      Rudwaleit M, Taylor WJ. Classification criteria for psoriatic arthritis and ankylosing spondylitis/axial spondyloarthritis. Best Pract Res Clin Rheumatol. 2010;24:589-604.
      Kearsley-Fleet L, Davies R, De Cock D, et al. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018;77:1405-1412.
      Dhaon P, Das SK, Srivastava R, Dhakad U. Performances of clinical disease activity index (CDAI) and simplified disease activity index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients. Int J Rheum Dis. 2018;21:1933-1939.
      Smolen JS, Aletaha D. Scores for all seasons: SDAI and CDAI. Clin Exp Rheumatol. 2014;32:S75-79.
      Palmieri L, Panico S, Vanuzzo D, et al. Gruppo di Ricerca del Progetto CUORE. evaluation of the global cardiovascular absolute risk: the Progetto CUORE individual score. Ann Ist Super Sanita. 2004;40:393-399.
      Agca R, Hopman LHGA, Laan KCJ, et al. Cardiovascular event risk in rheumatoid arthritis is higher than in type 2 diabetes: a 15 year longitudinal study. J Rheumatol. 2019.
      Cioffi G, Viapiana O, Ognibeni F, et al. Clinical profile and outcome of patients with rheumatoid arthritis and abnormally high aortic stiffness. Eur J Prev Cardiol. 2016;23:1848-1859.
      Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337-344.
      Crowson CS, Rollefstad S, Ikdahl E, Kitas GD, van Riel PLCM, Gabriel SE. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77:48-54.
      El Miedany Y. Co-morbidity index in rheumatoid arthritis: time to think. Clin Rheumatol. 2015;34:1995-2000.
      January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary. Circulation. 2014;130:2071-2104.
      Lackland DT, Roccella EJ, Deutsch AF, et al. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke. 2014;45:315-353.
      Goto S, Bhatt DL, Röther J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008;156:855-863.
      Ohira T, Shahar E, Chambless L, Rosamond W, Mosley T Jr, Folsom A. Risk factors for ischemic stroke subtypes. The atherosclerosis risk in communities (ARIC) study. Stroke. 2006;37:2493-2498.
      Arts EE, Popa C, Den Broeder AA, et al. Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis. 2015;74:668-674.
      Colaco K, Ocampo V, Ayala AP, et al. Predictive utility of cardiovascular risk prediction algorithms in inflammatory rheumatic diseases: a systematic review. J Rheumatol. 2019.
      Del Rincon I, O'Leary DH, Freeman GL, Escalante A. Acceleration of atherosclerosis during the course of rheumatoid arthritis. Atherosclerosis. 2007;195:354-360.
      Kao AH, Krishnaswami S, Cunningham A, et al. Subclinical coronary artery calcification and relationship to disease duration in women with rheumatoid arthritis. J Rheumatol. 2008;35:61-69.
      Cioffi G, Viapiana O, Ognibeni F, et al. Prevalence and factors related to inappropriately high left ventricular mass in patients with rheumatoid arthritis without overt cardiac disease. J Hypertens. 2015;33:2141-2149.
      Harrold LR, Litman HJ, Connolly SE, et al. A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice? Clin Rheumatol. 2017;36:1215-1220.
      Mikuls TR, Fay BT, Michaud K, et al. Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry. Rheumatology. 2011;50:101-109.
      Buch MH. Defining refractory rheumatoid arthritis. Ann Rheum Dis. 2018;77:966-969.
      Wallmann D, Tüller D, Wustmann K, et al. Frequent atrial premature beats predict paroxysmal atrial fibrillation in stroke patients: an opportunity for a new diagnostic strategy. Stroke. 2007;38:2292-2294.
      Gladstone DJ, Dorian P, Spring M, et al. Atrial premature beats predict atrial fibrillation in cryptogenic stroke: results from the EMBRACE trial. Stroke. 2015;46:936-941.
    • Contributed Indexing:
      Keywords: CHA2DS2-VASc score; ankylosing spondylitis; cardiovascular risk factors; clinical outcomes; psoriatic arthritis; rheumatoid arthritis
    • Publication Date:
      Date Created: 20191220 Date Completed: 20201119 Latest Revision: 20201119
    • Publication Date:
      20240829
    • Accession Number:
      10.1111/1756-185X.13751
    • Accession Number:
      31854508